BLAINJECTIONINJECTABLE
Approved
Aug 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
73
Data completeness
5/8 — Partial
REPATHA (evolocumab) by Amgen is pcsk9 inhibitors [moa]. Approved for pcsk9 inhibitor [epc]. First approved in 2015.
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REPATHA (evolocumab) is a monoclonal antibody PCSK9 inhibitor approved in 2015 for lowering LDL cholesterol in patients with hypercholesterolemia or cardiovascular disease. It works by binding and inhibiting PCSK9, a protein that regulates LDL receptor degradation, thereby increasing LDL clearance from the bloodstream. The drug is administered via subcutaneous injection and represents a major advancement in cardiovascular risk reduction.
Peak
REPATHA is at peak market penetration with moderate competitive pressure (30/100), indicating stable team size and established market position.
Mechanism of Action
PCSK9 Inhibitors
Pharmacologic Class:
PCSK9 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (73)
Mechanistic Clinical Trial of PCSK9 Inhibition for AAA
Started Dec 2026
44 enrolled
Abdominal Aortic Aneurysm
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.
Started Apr 2026
400 enrolled
Healthy Participants
A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab
Started Apr 2026
5,995 enrolled
Cardiovascular DiseasesAtherosclerotic Cardiovascular DiseaseHypercholesterolemia, Familial
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
Started Jan 2026
405 enrolled
Healthy ParticipantsPharmacokinetics
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
Started Dec 2024
69 enrolled
Dyslipidemias
Worked on REPATHA at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.